Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -5.75%18 Cash Ratio is 0.07 as of Mar. 2026, which is 67% below its 10-year median of 0.21. GuruFocus rates HKPD with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 117 Medical Distribution companies, Cellyan Biotechnology Co ranks better than 86.32% on this metric.
Cellyan Biotechnology Co has a Cash Ratio of 0.07. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Cellyan Biotechnology Co's Cash Ratio or its related term are showing as below:
HKPD'
s Cash Ratio Range Over the Past 10 Years
Min: 0.07 Med: 0.21 Max: 1.03
Current: 0.07
During the past 4 years, Cellyan Biotechnology Co's highest Cash Ratio was 1.03. The lowest was 0.07. And the median was 0.21.
HKPD's Cash Ratio is ranked better than 86.32% of 117
companies
in the Medical Distribution industry
Industry Median: 0.2
vs HKPD: 0.07
Cellyan Biotechnology Co (NAS:HKPD) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Cellyan Biotechnology Co Cash Ratio Related Terms
Cellyan Biotechnology Co Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Cash Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a Cash Ratio of 0.07 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cellyan Biotechnology Co and its competitors. This is 67% below median its historical median of 0.21. Over the past decade, Cellyan Biotechnology Co's Cash Ratio has ranged from 0.07 to 1.03. According to the industry distribution chart, Cellyan Biotechnology Co ranks #16 out of 117 companies in the Medical Distribution industry, placing it in the top 13.7%.
Is Cellyan Biotechnology Co's Cash Ratio too high?
Cellyan Biotechnology Co's current Cash Ratio of 0.07 is 67% below median its 10-year median of 0.21. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 1.03. The Medical Distribution industry median Cash Ratio is 0.20. Cellyan Biotechnology Co's value of 0.07 is 65% below this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #16 out of 117 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Cash Ratio compare to MEDS and COSM?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #16 out of 117 companies for Cash Ratio. This places Cellyan Biotechnology Co in the top 14% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 0.20. Cellyan Biotechnology Co's value of 0.07 is 65% below this benchmark. Historically, Cellyan Biotechnology Co's own Cash Ratio has ranged from 0.07 to 1.03 over the past decade. While the company's 10-year median is 0.21 vs. the industry median of 0.20, Cellyan Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Distribution company?
The median Cash Ratio among Medical Distribution companies is 0.20, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Cash Ratio of 0.07 is 65% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Cash Ratio is 0.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Cash Ratio is 0.07, which is 67% below median its own 10-year median of 0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Cash Ratio of 0.07. The current Cash Ratio is 0.07, which is 67% below median its 10-year median of 0.21 and 65% below the Medical Distribution industry median of 0.20. Cellyan Biotechnology Co's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Cash Ratio is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
18GF Score
Get the complete analysis for HKPD
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
